Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $1 | $1 | $1 |
| G&A Expenses | $0 | $2 | $2 | $2 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $2 | $3 |
| Operating Income | -$2 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$2 | -$2 | -$2 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |
| EPS | -1.23 | -1.89 | -2.14 | -3.27 |
| % Growth | 34.9% | 11.7% | 34.6% | – |
| EPS Diluted | -1.23 | -1.89 | -2.14 | -3.27 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $36 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $2 | $3 |
| EBITDA | -$2 | -$2 | $0 | $0 |
| % Margin | – | – | – | – |